CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 112 enrolled
Drug / intervention
FLULAVAL® QUADRIVALENTbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01440387
NCT01440387Phase 3Completed
CompareCT.gov

A Phase IIIA Study of Immunogenicity and Safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

GlaxoSmithKline·interventional·Posted Sep 26, 2011·Updated Sep 7, 2018

In Brief

A Phase 3 clinical trial evaluating FLULAVAL® QUADRIVALENT for Influenza. Completed, enrolled 112 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline (GSK) Biologicals' investigational quadrivalent split virion influenza vaccine FLU-Q-QIV in adults 18 years of age and older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 26, 2011
Enrollment StartSep 30, 2011
Primary CompletionOct 22, 2011
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 14.8 years ago

Interventions

FLULAVAL® QUADRIVALENTbiological

Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups